Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 12:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 79 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Nontuberculous Mycobacterium Infection Clear all
Recruiting No phase listed Observational

Transmission and Acquisition of Nontuberculous Mycobacteria Outbreak Investigation (TrANsMIt)

NCT06155747
View directory record Official record
Conditions
Nontuberculous Mycobacterial Pulmonary Infection, Outbreak Investigation, Healthcare Associated Infection, Mycobacterium Infections
Interventions
Epidemiologic investigation
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Month to 99 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jul 21, 2026, 12:43 PM EDT
Completed Phase 2 Interventional

A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS

NCT00001058
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Ethambutol hydrochloride, Clarithromycin, Rifabutin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
33
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 21, 2026, 12:43 PM EDT
Recruiting Phase 2 Interventional

Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin

NCT05730283
View directory record Official record
Conditions
Ototoxicity, Drug-Induced
Interventions
ORC-13661, Placebo
Drug
Lead sponsor
Kevin Winthrop
Other
Eligibility
18 Years to 80 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
San Francisco, California • Denver, Colorado • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 21, 2026, 12:43 PM EDT
Completed Phase 1 Interventional Results available

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis

NCT01585766
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing Forms
Interventions
MEDI-551 30 MG-IV, MEDI-551 60 MG-SC, PLACEBO-IV-SC, MEDI-551 100 MG-IV, MEDI-551 300 MG-SC, MEDI-551 600 MG-IV
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Scottsdale, Arizona • Long Beach, California • Sacramento, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2018 · Synced Jul 21, 2026, 12:43 PM EDT
Completed Not applicable Interventional

A Study to Evaluate the Effects of Azithromycin on MAC Disease Prevention in HIV-Positive Patients

NCT00000947
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Azithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
19
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Jul 21, 2026, 12:43 PM EDT
Completed Phase 3 Interventional

The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected Patients

NCT00001030
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Clarithromycin, Rifabutin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
41
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 21, 2026, 12:43 PM EDT
Terminated Phase 3 Interventional

ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

NCT06418711
View directory record Official record
Conditions
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
Interventions
Clofazimine Inhalation Suspension, Placebo
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 85 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
54
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jul 21, 2026, 12:43 PM EDT
Completed Phase 4 Interventional

Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM)

NCT00600769
View directory record Official record
Conditions
Nontuberculous Mycobacteria, Mycobacterium Avium Complex
Interventions
Clarithromycin
Drug
Lead sponsor
The University of Texas Health Science Center at Tyler
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2017
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Jul 21, 2026, 12:43 PM EDT
Recruiting Phase 1 Interventional

IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study)

NCT04294043
View directory record Official record
Conditions
Nontuberculous Mycobacterium Infection
Interventions
Gallium nitrate
Drug
Lead sponsor
Chris Goss
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Denver, Colorado • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Jul 21, 2026, 12:43 PM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease

NCT04553406
View directory record Official record
Conditions
Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease
Interventions
SPR720, Placebo, Open-label Standard of Care
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Altamonte Springs, Florida • Atlantis, Florida • Clearwater, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2022 · Synced Jul 21, 2026, 12:43 PM EDT
Completed Not applicable Interventional

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial

NCT00002032
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Rifabutin
Drug
Lead sponsor
Pharmacia
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
33
States / cities
Irvine, California • Sylmar, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 21, 2026, 12:43 PM EDT
Enrolling by invitation No phase listed Observational

Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria

NCT06262282
View directory record Official record
Conditions
Cystic Fibrosis, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection, Mycobacterium Infections, Mycobacterium; Pulmonary
Interventions
mycobacteriophage
Biological
Lead sponsor
National Jewish Health
Other
Eligibility
6 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Jul 21, 2026, 12:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 LEP-F1 + GLA-SE Vaccine Trial in Healthy Adult Volunteers

NCT03302897
View directory record Official record
Conditions
Leprosy
Interventions
LEP-F1 + GLA-SE
Biological
Lead sponsor
Access to Advanced Health Institute (AAHI)
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Jul 21, 2026, 12:43 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effects of Interleukin-12 (rhIL-12) in HIV-Positive Patients With CD4 Cell Counts Less Than 50 Cells/mm3 or 300-500 Cells/mm3

NCT00000857
View directory record Official record
Conditions
HIV Infections
Interventions
Interleukin-12
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
16
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Jul 21, 2026, 12:43 PM EDT
Completed Phase 2 Interventional

A Randomized, Double-Blinded, Placebo-Controlled, Phase II Inhaled Interferon Gamma-1b and Antimycobacterials to Treat Pulmonary Mycobacterium Avium Complex Infections

NCT00021567
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection
Interventions
Interferon Gamma for Aerosol
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 21, 2026, 12:43 PM EDT
Completed Phase 3 Interventional

A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients

NCT00002122
View directory record Official record
Conditions
Mycoses, Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Azithromycin, Rifabutin, Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
12
States / cities
Los Angeles, California • Orange, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 21, 2026, 12:43 PM EDT
Completed Phase 2 Interventional Results available

A Proof of Concept Study of Inhaled Nitric Oxide for Adults With Pulmonary Non-Tuberculous Mycobacterial Infection

NCT03748992
View directory record Official record
Conditions
Nontuberculous Mycobacterium Infection
Interventions
gNO
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Portland, Oregon • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Jul 21, 2026, 12:43 PM EDT
Completed Phase 2 Interventional

Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia.

NCT00002192
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Rifapentine, Ethambutol hydrochloride, Clarithromycin, Azithromycin
Drug
Lead sponsor
Anderson Clinical Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Hampton, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 21, 2026, 12:43 PM EDT
Completed Not applicable Interventional

A Study of Azithromycin in the Prevention of Mycobacterium Avium Complex Disease (MAC) in HIV-Infected Patients

NCT00002309
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Azithromycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
San Diego, California • Fort Bragg, North Carolina • Lackland Air Force Base, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 21, 2026, 12:43 PM EDT
Terminated Phase 2 Interventional

Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease

NCT04154826
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous
Interventions
Recombinant human interleukin-7
Drug
Lead sponsor
Revimmune
Industry
Eligibility
18 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Jul 21, 2026, 12:43 PM EDT
Completed Phase 2 Interventional Results available

Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

NCT04922554
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous, Mycobacterium Abscessus Infection, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterial Pulmonary Infection
Interventions
Omadacycline Oral Tablet, Placebo
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
17
States / cities
Stanford, California • Washington D.C., District of Columbia • Clearwater, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Jul 21, 2026, 12:43 PM EDT
Completed Phase 2 Interventional

A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. Avium Complex (MAC) Infections in Patients With AIDS

NCT00000644
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Clarithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 24, 2011 · Synced Jul 21, 2026, 12:43 PM EDT
Completed Not applicable Interventional

Long-Term Assessment for Metabolic, Cardiovascular and Neurologic Problems in HIV-Infected Patients With Increased CD4 Cells Counts Following Anti-HIV Therapy

NCT00000883
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Azithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
51
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Jul 21, 2026, 12:43 PM EDT
Completed Phase 1Phase 2 Interventional

Sildenafil for PNTM Infection

NCT01853540
View directory record Official record
Conditions
Nontuberculous Mycobacterial Infection
Interventions
Sildenafil
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Jul 21, 2026, 12:43 PM EDT